|
|
|
| Serum Levels of Histone Deacetylase 2 Interleukin-1 beta Interleukin-6 and Interleukin-17A in Patients with COPD and Clinical Significance |
| CAO Lu, GAO Baoan, GUAN Li, et al |
| Yichang Central People's Hospital / Institute of Respiratory Diseases,Three Gorges University, Hubei Yichang 443000, China |
|
|
|
|
Abstract Objective: To explore the plasma histone acetylation enzyme 2, interleukin 1, interleukin 6 and interleukin 17A levles of patients with COPD and the clinical significance. Methods: 64 COPD patients were retrospectively chosen as the observation group in our respiratory intensive care unit from June 2016 to June 2018. While, 64 cases of normal physical health people were selected as the control group. Serum HDAC2, IL-1β, IL-6 and IL-17A levels were determined by ELISA. FEV1/FVC% and FEV1% pred values were detected by the lung function detector. Pearson correlation analysis was performed to explore the correlation between serum HDAC2, IL-1β, IL-6 and IL-17A levels and lung function. Results: Compared with the control group, serum HDAC2, IL-1β, IL-6 and IL-17A levels were significantly increased in the observation group (P<0.05). Serum HDAC2, IL-1β, IL-6 and IL-17A levels of observation group were gradually increased with the lung function grade increase (P<0.05). FEV1/FVC%,FEV1% pred of COPD patients with different levels of lung function decreased gradually with the increase of grade, and the comparison difference results were statistically significant (P<0.05). Pearson correlation analysis showed that serum HDAC2 level was positively correlated with lung function. While, IL-1β, IL-6 and IL-17A levels were negatively correlated with lung function FEV1/FVC% and FEV1% pred (P<0.05). Conclusion: The expression of histone deacetylase 2 was decreased, IL-1β, IL-6 and IL-17A levels of COPD patients were significant increased. The inflammation of patient airway and alveolar tissue were activated, which might be one of the main factors of progressive decline of lung function.
|
|
|
|
|
|
[1] 杨凌婧.稳定期中重度慢阻肺患者血清IL-6、IL-8、TNF-α、hs-CRP与肺功能的相关性研究[J].临床肺科杂志,2016,21(3):481~484
[2] 陈炜,张念志,韩明向.四子温肺汤对慢阻肺急性加重期患者IL-17A、HIF-1α表达影响的研究[J].时珍国医国药,2016,27(7):1602~1604.
[3] 邝相如.白介素-6、降钙素原、D-二聚体与慢阻肺急性加重期患者病情及预后相关性研究[D].河北医科大学,2016.
[4] 陈炜,张念志,张一萌,等.益气活血化痰法对慢性阻塞性肺疾病大鼠HIF-1α、IL-17A表达影响研究[J].辽宁中医药大学学报,2017,19(3):25~27.
[5] 谭杰,康艳虹,苏燕娜,等.慢性阻塞性肺疾病急性加重期患者血清PCT、IL-6、hs-CRP水平与肺功能的相关性研究[J].广州医药,2017,48(3):93~95.
[6] 潘建丽,黄伦,欧灵,等.外周血白介素-17检测在气道慢性炎症性疾病诊断中的临床价值[J].中华肺部疾病杂志(电子版),2016,9(5):479~483.
[7] 赖天文.组蛋白去乙酰化酶2及白介素17A在慢阻肺及哮喘中的分子机制研究[D].浙江大学,2017.
[8] 谭春婷,王浩彦.组蛋白去乙酰化酶2与慢性阻塞性肺疾病[J].中国呼吸与危重监护杂志,2015,14(4):410~413.
[9] Ito K,Ito M,Elliott W,et al.,Decreased histone deacetylase activity in chronic obstructive pulmonary disease[J].N Engl Med,2005,352:1967~1976.
[10] 孙娴雯,李庆云,万欢英.组蛋白去乙酰化酶-2与慢性阻塞性肺疾病的糖皮质激素治疗[J].上海医学,2011,34(3):240~242. |
|
|
|
2019, Vol. 25 
